Article focus {#section5-2046-3758.71.BJR-2017-0323}
=============

-   Serum biomarkers remain a fundamental part of the evaluation and diagnosis of hip and knee periprosthetic joint infection. This article explores the evidence for promising new serum markers and explores factors affecting conventional serum testing, in order to enable clinicians to accurately interpret these tests.

-   Currently, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) continue their role as first-line screening tests for PJI. However, due to the lack of specificity, these tests are complemented by more specific synovial tests and microbiology findings, and should not be utilized alone in the diagnosis of PJI.

-   Other serum biomarkers have not demonstrated superior sensitivity and have failed to replace CRP and ESR as first-line screening tests.

Key messages {#section6-2046-3758.71.BJR-2017-0323}
============

-   Our review helped identify factors that can influence serum biomarkers' level changes; the recognition of such factors can help improve their diagnostic utility.

-   As such, we cannot rely on ESR and CRP alone for the diagnosis of PJI prior to second-stage reimplantation, or in metal-on-metal or corrosion cases.

-   D-dimer appears to be a promising biomarker, but more research is necessary.

Strengths and limitations {#section7-2046-3758.71.BJR-2017-0323}
=========================

-   This review included the most recently published articles and the most up-to-date research on periprosthetic joint infection detection measures (within five years). However, we did not exclude landmark studies published before the selected window.

-   The literature review was comprehensive and included all serum biomarkers reported in the literature, their correlation with periprosthetic joint infection, and factors that can influence the serum biomarkers levels. However, the focus of the search was only for total hip and total knee arthroplasty studies; other forms of arthroplasty were excluded (shoulder or elbow).

Introduction {#section8-2046-3758.71.BJR-2017-0323}
============

Periprosthetic joint infection (PJI) is a dreaded complication of total hip and knee arthroplasty. It poses a challenge to the orthopaedic surgeon with regards to prevention, diagnosis, and management. The diagnosis of PJI has been a subject of extensive research in recent years, as surgical management will require implant removal and possibly delayed reimplantation (two-stage revision).^[@bibr1-2046-3758.71.BJR-2017-0323]--[@bibr3-2046-3758.71.BJR-2017-0323]^ Therefore, having an accurate preoperative diagnosis is critical for surgical planning and managing patient expectations.^[@bibr4-2046-3758.71.BJR-2017-0323],[@bibr5-2046-3758.71.BJR-2017-0323]^

In an effort to standardize the diagnosis of PJI, the Musculoskeletal Infection Society (MSIS) convened a workgroup in 2011 to issue diagnostic criteria for PJI;^[@bibr6-2046-3758.71.BJR-2017-0323]^ this was later modified in 2014.^[@bibr7-2046-3758.71.BJR-2017-0323]^ Some of the criteria included in this definition are only available to the surgeon intraoperatively (histology, presence of purulence) or postoperatively (microbiology), and therefore do not contribute towards a preoperative plan. Hence, more recent research has focused on preoperative criteria, such as synovial fluid tests (white blood cell count (WBC) and leucocyte esterase) and serological tests (conventional C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR)). While synovial biomarkers have generally shown superior accuracy compared to serum biomarkers,^[@bibr8-2046-3758.71.BJR-2017-0323],[@bibr9-2046-3758.71.BJR-2017-0323]^ serum tests remain the less invasive, first-line screening tool. The search continues for an ideal serum biomarker that offers high sensitivity and specificity to limit invasive and unnecessary joint arthrocentesis and extensive infection workup.

The purpose of this review is to summarize current evidence of the diagnostic accuracy of conventional serum biomarkers, and to explore the evidence for promising new serum markers. Furthermore, we explored factors affecting conventional serum testing, in order to enable clinicians to accurately interpret these tests.

Patients and Methods {#section9-2046-3758.71.BJR-2017-0323}
====================

Search strategy and selection criteria {#section10-2046-3758.71.BJR-2017-0323}
--------------------------------------

We searched MEDLINE (1946 to 10 February 2017) and EMBASE (1974 to 08 February 2017). We used search terms that encompass all hip and knee arthroplasty procedures, as well as periprosthetic joint infection. The search also included an extensive list of biomarkers and statistical terms reflecting diagnostic parameters, such as sensitivity, specificity, and diagnostic odds ratio. We also searched the reference lists of articles identified by this search strategy and selected those we judged relevant. After duplicates were removed, the search resulted in 556 articles. Only total hip and total knee arthroplasty studies were included; other forms of arthroplasty were excluded (shoulder or elbow). We largely selected articles published within the past five years, but did not exclude older articles that are commonly referenced and highly regarded. Articles evaluating synovial biomarkers were also excluded, as the focus of this review is limited to serum biomarkers.

Parameters of diagnostic performance {#section11-2046-3758.71.BJR-2017-0323}
------------------------------------

Interpreting studies of diagnostic tests requires an understanding of the many indicators of test performance. A brief introduction to these different indicators is therefore necessary. In the context of PJI, patients are grouped as either infected or noninfected. Such a dichotomization enables one to represent the comparison between a diagnostic test and its reference standard in a 2 × 2 contingency table ([Table I](#table1-2046-3758.71.BJR-2017-0323){ref-type="table"}). Common indicators derived from such a 2 × 2 table are the sensitivity and specificity of the test, the positive and negative predictive values, and the positive and negative likelihood ratios ([Table II](#table2-2046-3758.71.BJR-2017-0323){ref-type="table"}). None of these indicators validly represents the test's discriminatory performance. Sensitivity is only part of the discriminatory evidence, as high sensitivity may be accompanied by low specificity. Additionally, no simple aggregation rule exists to combine sensitivity and specificity into one measure of performance.

###### 

2 × 2 contingency table

                       Reference test (e.g. MSIS definition)   
  -------------------- --------------------------------------- ----------------
  New test: positive   True positive                           False positive
  New test: negative   False negative                          True negative

MSIS, Musculoskeletal Infection Society

###### 

Commonly used test parameters in diagnostic studies

  Parameter                                              Formula                           Definition
  ------------------------------------------------------ --------------------------------- ----------------------------------------------------------------------------------------------
  Sensitivity                                            TP / (TP + FN)                    Proportion of positive result in infected patients
  Specificity                                            TN / (TN + FP)                    Proportion of negative result in noninfected patients
  Positive predictive value (PPV)                        TP / (TP + FP)                    Proportion of infection among patients with a positive result
  Negative predictive value (NPV)                        TN / (TN + FN)                    Proportion of no infection among patients with a negative result
  Positive likelihood ratio (LR+)                        Sensitivity / (1 - specificity)   Ratio of a positive result in infected patients to a positive result in noninfected patients
  Negative likelihood ratio (LR-)                        (1 - sensitivity) / specificity   Ratio of a negative result in infected patients to a negative result in noninfected patients
  Accuracy                                               (TP +TN) / (TP + TN + FP + FN)    Global measure of performance
  Youden's index^[@bibr10-2046-3758.71.BJR-2017-0323]^   Sensitivity + specificity - 1     Global measure of performance

TP, true positive; FP, false positive; FN, false negative; TN, true negative

Single indicators of test performance include accuracy, Youden's index,^[@bibr10-2046-3758.71.BJR-2017-0323]^ receiver operating characteristic (ROC) curve, and the diagnostic odds ratio (DOR). Accuracy refers to the percentage of patients correctly classified by the test under evaluation. This percentage depends on the prevalence of the PJI in the study group whenever sensitivity and specificity are not equal, and it weighs false positive and false negative findings equally. Youden's index is derived from sensitivity and specificity; as such, it is independent of prevalence.^[@bibr10-2046-3758.71.BJR-2017-0323]^ However, because Youden's index is a linear transformation of the mean sensitivity and specificity, its values are difficult to interpret.^[@bibr10-2046-3758.71.BJR-2017-0323]^

The ROC curve is a plot of all pairs of sensitivity and specificity values for every cutoff value ([Fig. 1](#fig1-2046-3758.71.BJR-2017-0323){ref-type="fig"}). The shape of a ROC curve and the area under the curve (AUC) helps estimate the discriminative power of a test. The closer the curve is located on the upper-left hand corner and the larger the area under the curve, the better the test is at discriminating between infected and noninfected patients. AUC can have values between 0 and 1. A perfect test has an AUC of 1, whereas a nondiscrimination test has an AUC of 0.5. AUC is a global measure of diagnostic accuracy. For example, two different tests may have identical AUCs, but one can have significantly higher sensitivity, whereas the other can have significantly higher specificity. Global measures like AUC are used for general assessment and for comparison of two or more diagnostic tests. DOR is another global measure, and it represents the ratio of the odds of positivity in infected patients relative to the odds of positivity in noninfected patients. The value of DOR ranges from 0 to infinity, with higher values indicating better discriminatory test performance. A value of 1 means that a test does not discriminate between infected and noninfected patients.^[@bibr11-2046-3758.71.BJR-2017-0323]^

![Receiver operating characteristic (ROC) curve](bonejointres-07-85-g001){#fig1-2046-3758.71.BJR-2017-0323}

Results {#section12-2046-3758.71.BJR-2017-0323}
=======

Diagnostic efficacy {#section13-2046-3758.71.BJR-2017-0323}
-------------------

### Erythrocyte sedimentation rate and C-reactive protein {#section14-2046-3758.71.BJR-2017-0323}

ESR and CRP are by far the most commonly published serum biomarkers in PJI literature. ESR has been known to be elevated in inflammatory conditions since 1921, when Westergren^[@bibr12-2046-3758.71.BJR-2017-0323]^ recognized the usefulness of ESR in tuberculosis.^[@bibr13-2046-3758.71.BJR-2017-0323]^ Increases in fibrinogen and other normal plasma proteins, and the presence of abnormal circulating proteins derived from necrotic tissue, can enhance red-cell aggregation and accelerate the settling of erythrocytes, thus increasing the measured ESR. CRP is an archetype acute phase protein found in 1930 by Tillett and Francis.^[@bibr14-2046-3758.71.BJR-2017-0323],[@bibr15-2046-3758.71.BJR-2017-0323]^ It is produced by the liver with maximum production 24 to 35 hours after inflammation onset. Studies using liver tissue cultures show that interleukin-6 (IL-6) is a massive inducer of CRP microRNA in liver cells. CRP binds Gram-positive and Gram-negative bacteria and stimulates their adhesion and phagocytosis by leucocytes. It is not a specific parameter for the presence of infectious induced inflammation, as it is also elevated in systemic autoimmune diseases such as rheumatoid arthritis, after trauma, or after surgery and tissue damage.^[@bibr16-2046-3758.71.BJR-2017-0323]^ On the other hand, its concentration decreases with the use of systemic corticosteroids.^[@bibr17-2046-3758.71.BJR-2017-0323]^

Due to their high sensitivity and routine accessibility, ESR and CRP currently remain as first-line screening tests for PJI. The articles included in this review showed that the sensitivity and specificity of ESR ranges from 42% to 94%, and 33% to 87%, respectively.^[@bibr18-2046-3758.71.BJR-2017-0323]-[@bibr24-2046-3758.71.BJR-2017-0323]^ CRP had sensitivities and specificities ranging from 74% to 94%, and 20% to 100%, respectively. If a positive ESR or CRP is considered the threshold for infection, the sensitivity is increased up to 97% but the specificity can be as low as 23%.^[@bibr21-2046-3758.71.BJR-2017-0323]^ On the other hand, if a positive ESR and a positive CRP is considered the threshold for infection, specificity is enhanced up to 93%, at the cost of sensitivity.^[@bibr20-2046-3758.71.BJR-2017-0323]^

Even in patients with inflammatory conditions, ESR and CRP are still helpful diagnostic tools. Cipriano et al^[@bibr25-2046-3758.71.BJR-2017-0323]^ aimed to evaluate the performance of ESR and serum CRP in diagnosing PJI in patients with inflammatory arthritis as opposed to noninflammatory arthritis. They found similar accuracy for both ESR and CRP in both inflammatory and noninflammatory groups (ESR AUC, 0.85 and 0.85, respectively; CRP AUC, 0.88 and 0.85, respectively). However, due to their modest specificity, relying solely on ESR and CRP in complex clinical scenarios is not appropriate.

### Interleukin-6 (IL-6) {#section15-2046-3758.71.BJR-2017-0323}

IL-6 is an inflammatory cytokine produced by stimulated monocytes and macrophages. It induces the production of acute-phase proteins, including CRP, and acts as a differentiating factor for B-lymphocytes and an activating factor for T-lymphocytes. A meta-analysis published in 2010 attracted attention to serum IL-6 as a potential superior diagnostic test compared with the conventional ESR and CRP.^[@bibr26-2046-3758.71.BJR-2017-0323]^ In this meta-analysis, the pooled sensitivity and specificity for IL-6 were 97% and 91%, respectively. Its DOR was higher than that for ESR and CRP. However, the data were mainly driven by one large and two smaller studies.^[@bibr27-2046-3758.71.BJR-2017-0323],[@bibr28-2046-3758.71.BJR-2017-0323]^ More recent studies have found the diagnostic performance of serum IL-6 comparable to CRP. Glehr et al^[@bibr29-2046-3758.71.BJR-2017-0323]^ performed a prospective study including 124 revision arthroplasties and used MSIS criteria. IL-6 had a sensitivity, a specificity, and an AUC of 81%, 68%, and 0.80, respectively. CRP, in comparison, had an AUC of 0.9. Ettinger et al^[@bibr30-2046-3758.71.BJR-2017-0323]^ also used MSIS criteria in a prospective study to evaluate IL-6; with a cutoff value of 5.12 pg/ml, the authors found it to be 80% sensitive and 87.7% specific. Gollwitzer et al^[@bibr31-2046-3758.71.BJR-2017-0323]^ prospectively evaluated 35 patients undergoing revision total hip arthroplasty (THA) and total knee arthroplasty (TKA), including only purulent infection cases with *Staphylococcus* species, and compared them with aseptic loosening. Their criteria for infection included clinical exam (sinus tract), intraoperative cultures, histology findings, and CRP. Serum IL-6 had a sensitivity of 0.48, a specificity of 0.95, and an AUC of 0.687. Randau et al^[@bibr32-2046-3758.71.BJR-2017-0323]^ also performed a prospective study of 120 patients undergoing revision TKA and THA, and reported a sensitivity and specificity of IL-6 ranging from 49% to 79%, and 58% to 88%, respectively, depending on the cutoff value used. This variability and lack of consistency in the results have limited its implementation as a screening test to replace serum CRP and ESR.

### White blood cell count (WBC) {#section16-2046-3758.71.BJR-2017-0323}

While synovial WBC count and differential is one of the main diagnostic criteria for PJI, serum WBC count has very little utility. In a prospective study of 120 patients that underwent revision THA and TKA, Friedrich et al^[@bibr33-2046-3758.71.BJR-2017-0323]^ found a sensitivity of 21% and a specificity of 94% for serum WBC when using microbiology and histology data as a reference test. In another prospective study of 78 patients that underwent revision THA and TKA, Bottner et al^[@bibr27-2046-3758.71.BJR-2017-0323]^ found it to be 70% sensitive and 60% specific. Overall, these findings limit its utility in the diagnosis of PJI.

### Procalcitonin {#section17-2046-3758.71.BJR-2017-0323}

In the past 15 years, procalcitonin (PCT) has gained ground as a biomarker for sepsis.^[@bibr34-2046-3758.71.BJR-2017-0323]^ Procalcitonin is a protein produced by neuroendorcine cells and the parafollicular cells of the thyroid under physiological conditions. In sepsis, the main producers of PCT are macrophages and monocytic cells of different organs, especially the liver.^[@bibr15-2046-3758.71.BJR-2017-0323]^ PCT was found to have a high diagnostic accuracy for the identification of systemic infection.^[@bibr35-2046-3758.71.BJR-2017-0323]^ However, its diagnostic value for detecting PJI is uncertain. A recent meta-analysis helped to compile the results of six studies evaluating the diagnostic efficacy of PCT in PJI ([Table III](#table3-2046-3758.71.BJR-2017-0323){ref-type="table"}).^[@bibr36-2046-3758.71.BJR-2017-0323]^ PCT was found to have a pooled sensitivity, specificity, DOR, and AUC of 53%, 92%, 13, and 0.76 respectively ([Fig. 2](#fig2-2046-3758.71.BJR-2017-0323){ref-type="fig"}). Based on these results, serum PCT is not an ideal biomarker for the diagnosis of PJI because of its low sensitivity and small AUC.

###### 

Characteristics of six studies evaluating procalcitonin (PCT) for the diagnosis of periprosthetic joint infection (PJI)

  Study                                                           No. of patients   Study design   Cutoff                    Joint                 Reference test
  --------------------------------------------------------------- ----------------- -------------- ------------------------- --------------------- --------------------------------------------------
  Yuan et al,^[@bibr67-2046-3758.71.BJR-2017-0323]^ 2015          75                Prospective    0.5 ng/ml                 Hip                   Histology, intraoperative findings
  Ettinger et al,^[@bibr30-2046-3758.71.BJR-2017-0323]^ 2015      77                Prospective    0.025 ng/ml               Hip, knee, shoulder   Histology, microbiology, intraoperative findings
  Randau et al,^[@bibr32-2046-3758.71.BJR-2017-0323]^ 2014        120               Prospective    46 ng/ml                  Hip, knee             Histology, microbiology, intraoperative findings
  Glehr et al,^[@bibr29-2046-3758.71.BJR-2017-0323]^ 2013         124               Prospective    0.35 ng/ml; 0.055 ng/ml   Hip, knee             Histology, microbiology, intraoperative findings
  Worthington et al,^[@bibr39-2046-3758.71.BJR-2017-0323]^ 2010   46                Prospective    0.5 ng/ml                 Hip                   Microbiology
  Bottner et al,^[@bibr27-2046-3758.71.BJR-2017-0323]^ 2007       78                Prospective    0.3 ng/ml                 Hip, knee             Histology, intraoperative findings

Reproduced with permission from: **Xie K, Qu X, Yan M**. Procalcitonin and alpha-Defensin for Diagnosis of Periprosthetic Joint Infections. *J Arthroplasty* 2017;32:1387-1394. The reference numbers given in the 'Study' column correspond with the reference list in this paper, not the reference list given by Xie et al in their original study

![Summary receiver operating characteristic curves and forest plot for procalcitonin. Reproduced with permission from: **Xie K, Qu X, Yan M.** Procalcitonin and alpha-Defensin for Diagnosis of Periprosthetic Joint Infections. *J Arthroplasty* 2017;32:1387-1394. CI, confidence interval; AUC, area under the curve.](bonejointres-07-85-g002){#fig2-2046-3758.71.BJR-2017-0323}

### Other biomarkers {#section18-2046-3758.71.BJR-2017-0323}

Several other potential serum biomarkers have been identified in recent literature. One promising biomarker is D-dimer, a widely available serum biomarker that is known for its diagnostic utility of fibrinolytic activities in thromboembolic events, and that has demonstrated high sensitivity in the diagnosis of PJI.^[@bibr37-2046-3758.71.BJR-2017-0323]^ In an ongoing prospective cohort of 154 patients, Shahi et al^[@bibr37-2046-3758.71.BJR-2017-0323]^ found D-dimer to be have better sensitivity (97.7%) and specificity (93.6%) than ESR and CRP. D-dimer is an easily accessible assay in common routine practice, but more studies that reproduce these findings are needed to confirm its superiority to the conventional ESR and CRP.

Tumour necrosis factor-a (TNF-a) is another acute-phase inflammatory cytokine released by monocytes and macrophages that has been investigated in PJI. Two studies evaluated TNF-a using older PJI criteria^[@bibr27-2046-3758.71.BJR-2017-0323]^ and, more recently, MSIS criteria.^[@bibr30-2046-3758.71.BJR-2017-0323]^ Both showed similar diagnostic parameters: low sensitivity (43% and 35%) and high specificity (94% and 86%). Technical drawbacks include long processing times (over two hours) and the instability of the sample, which means it needs to be processed within 60 minutes of being drawn.^[@bibr27-2046-3758.71.BJR-2017-0323]^ Therefore, based on these results, TNF-a is not an ideal serum screening test for PJI.

Intercellular adhesion molecule-1 (ICAM-1) is a membrane glycoprotein that plays a key role in leucocyte migration and activation that has also been studied in the context of PJI. Drago et al^[@bibr38-2046-3758.71.BJR-2017-0323]^ studied ICAM-1 in a small sample of 52 patients undergoing revision hip or knee arthroplasty. Their definition of PJI depended largely on clinical signs and positive cultures. While they did not describe diagnostic parameters of ICAM-1, they found it to be significantly elevated in PJI patients compared with noninfected patients. Similarly, Worthington et al^[@bibr39-2046-3758.71.BJR-2017-0323]^ found ICAM-1 levels to be elevated in PJI patients. However, they did not specify which diagnostic parameters were used to define PJI. Further research quantifying its diagnostic performance is necessary before considering ICAM-1 as a clinically relevant serum biomarker for diagnosis of PJI.

Lipopolysaccharide-binding protein (LBP) is a polypeptide synthesized in hepatocytes when induced by IL-1, or synergistically by IL-1 and IL-6; the latter response can be enhanced by TNF-a.^[@bibr40-2046-3758.71.BJR-2017-0323],[@bibr41-2046-3758.71.BJR-2017-0323]^ LBP facilitates bacterial lipopolysaccharide binding to CD14, which is present on monocytes and macrophages. Elevated LBP levels have been reported in neonatal early sepsis. While LBP may theoretically be a potential biomarker for PJI, two separate clinical studies showed little clinical utility with low sensitivity and specificity for PJI.^[@bibr30-2046-3758.71.BJR-2017-0323],[@bibr33-2046-3758.71.BJR-2017-0323]^

Flow cytometry is another diagnostic method that has been investigated in the context of sepsis. This includes evaluating CD64 surface marker expression on neutrophils. CD64 can be used as a marker for neutrophil activation. While this has not been studied in PJI patients, Fjaertoft et al^[@bibr42-2046-3758.71.BJR-2017-0323]^ conducted a study to test whether CD64 level can differentiate between inflammation caused by bacterial infection *versus* inflammation brought on by surgical trauma. The authors found its expression to be significantly higher in infected patients, rather than those who underwent uncomplicated primary total hip arthroplasty (THA). The authors concluded that the expression of CD64 on neutrophils is a specific sign of bacterial infection. There are currently no studies comparing CD64 levels in noninfected arthroplasty patients with PJI patients.

Trends and factors affecting serum biomarkers {#section19-2046-3758.71.BJR-2017-0323}
---------------------------------------------

There is considerable variation in the literature with regards to appropriate thresholds for common serum biomarkers. In particular, ESR and CRP are nonspecific markers, and their measurement is affected by a variety of factors, including temporal trends, stage of inflammation (first-stage revision or explantation *versus* second-stage revision or reimplantation), patient factors (age, gender, underlying disease, medication), and implant factors (metal-on-metal bearing surfaces and corrosion).

### Normal temporal trends {#section20-2046-3758.71.BJR-2017-0323}

Time after index arthroplasty can have a confounding influence on ESR and CRP.^[@bibr20-2046-3758.71.BJR-2017-0323],[@bibr43-2046-3758.71.BJR-2017-0323]^ In an effort to describe normal temporal trends of ESR and CRP, Park et al^[@bibr43-2046-3758.71.BJR-2017-0323]^ prospectively evaluated 320 total knee arthroplasties performed in 214 consecutive patients without developing infection for more than one year. They measured ESR and CRP at several timepoints and compared unilateral TKAs with staged bilateral TKAs. According to their results, CRP increased rapidly on the second day, then decreased rapidly from peak levels within two weeks, and reached normal levels by the 42nd day ([Fig. 3](#fig3-2046-3758.71.BJR-2017-0323){ref-type="fig"}). In contrast, ESR levels reached peaked levels on the fifth day, and remained increased elevated above 20 mm/hour on the 42nd day. It returned to close to preoperative levels on the 90th day. These temporal trends were similar between unilateral and staged bilateral TKAs.

![Line graphs showing the temporal patterns of perioperative mean levels of A) C-reactive protein and B) Erythrocyte sedimentation rate (ESR) in unilateral, first knee bilateral, and second knee bilateral groups. Values with statistical significance are marked with a black box (■) for the comparisons between the unilateral and the second knee bilateral groups and with a white box (□) for the comparisons between the first knee bilateral and the second knee bilateral groups. Reproduced with permission from: **Park KK, Kim TK, Chang CB, Yoon SW, Park KU**. Normative Temporal Values of CRP and ESR in Unilateral and Staged Bilateral TKA. *Clin Orthop Relat Res* 2008;466:179-188.](bonejointres-07-85-g003){#fig3-2046-3758.71.BJR-2017-0323}

Alijanipour et al^[@bibr44-2046-3758.71.BJR-2017-0323]^ also sought to define thresholds values for ESR and CRP in hip *versus* knee PJI, and for early postoperative and late-chronic PJI. In their institutional database of revision arthroplasty cases, the authors identified 108 hip PJI and 165 knee PJI cases based on the MSIS criteria. The authors used the four-week mark to separate early from late PJI. ESR values were not statistically different between hip and knee PJI, but median CRP values were higher in knee PJI (13.3 mg/dl) compared with hip PJI (7.3 mg/dl, p = 0.02). For ESR, the authors proposed a higher threshold of 54.5 mm/hour in early postoperative PJI, and 46.5 mm/hour in late-chronic PJI. For CRP, the threshold in early hip and knee PJI was 2.3 mg/dl, but in late-chronic PJI was 1.3 mg/dl for hips and 2.3 mg/dl for knees.

### Trends prior to second-stage re-implantation {#section21-2046-3758.71.BJR-2017-0323}

Two-stage revision arthroplasty of infected prosthetic joints is commonly performed in North America as definitive treatment of PJI.^[@bibr45-2046-3758.71.BJR-2017-0323],[@bibr46-2046-3758.71.BJR-2017-0323]^ Determining whether a patient who has undergone the first stage of a staged revision arthroplasty is ready for reimplantation is a diagnostic dilemma. These patients have recently undergone explantation, typically in the six to eight weeks prior, which affects nonspecific inflammatory markers such as ESR and CRP. A progressively decreasing ESR and CRP have been considered favourable indicators for reimplantation in the absence of clinical signs of PJI.^[@bibr47-2046-3758.71.BJR-2017-0323]^

Ghanem et al^[@bibr48-2046-3758.71.BJR-2017-0323]^ retrospectively reviewed revision arthroplasty database at one institution and identified 109 consecutive patients who underwent two-stage revision arthroplasty. The authors measured serum ESR and CRP at a mean of 13 days prior to reimplantation (a mean of 94 days after first-stage explantation). The decision to proceed with the second-stage procedure was based on the absence of clinical signs of infection and on negative aspirate cultures. Using persistent PJI requiring further operation after the reimplantation procedure as an outcome measure, ESR and CRP both showed poor sensitivity and specificity (AUC of 0.5 and 0.54, respectively) in predicting persisting infection. The failure of ESR to emerge as a valuable marker in predicting persistent infection is not surprising, considering that normalization may not occur for at least three months.^[@bibr43-2046-3758.71.BJR-2017-0323]^ Similarly, Shukla et al^[@bibr49-2046-3758.71.BJR-2017-0323]^ reported poor accuracy of ESR and CRP prior to second-stage reimplantation of 87 patients with hip PJI. They found synovial fluid WBC count to be the best test for identifying infection (sensitivity, 78%; specificity, 96%). Kusuma et al^[@bibr50-2046-3758.71.BJR-2017-0323]^ showed that while ESR and CRP levels decreased between first stage and second stage, they were unable to identify an optimum cutoff value due to their poor diagnostic performance.

More recently, Hoell et al^[@bibr51-2046-3758.71.BJR-2017-0323]^ investigated the diagnostic accuracy of IL-6 prior to second-stage reimplantation. The authors reviewed 55 patients with hip and knee PJI defined by growing the same organism in at least two periprosthetic tissue cultures. Of those, 16 were found to have persistent infection (two positive cultures from at least three cultures at the time of reimplantation). Serum IL-6 had an AUC of 0.896 and an optimal cutoff value of ⩾ 13 pg/ml, indicating persistent infection; ⩽ 8 indicated absence of infection, and a range of nine to 12 was indeterminate. The authors also evaluated serum CRP, which was found to have an AUC of 0.704, higher than what has been reported in previous studies. When a cutoff value of \> 2.5 mg/dl is used, CRP has a sensitivity of 43.7% and specificity of 92.3%. It is possible that serum IL-6 may have a role in deciding infection eradication prior to second-stage reimplantation, but more research is necessary to confirm these findings.

Currently, there is no ideal serum biomarker with which to identify persistent infection prior to second-stage reimplantation. Research studies in this area have been hampered by the small sample size and the lack of a uniform definition for success or failure of second-stage procedures. Studies from our institution showed that MSIS criteria, the so-called benchmark for diagnosing PJI, are not useful for determining infection resolution of PJI after explantation.^[@bibr52-2046-3758.71.BJR-2017-0323],[@bibr53-2046-3758.71.BJR-2017-0323]^ Frangiamore et al^[@bibr52-2046-3758.71.BJR-2017-0323]^ reported on 35 patients with antibiotic cement spacer before second-stage reimplantation with a minimum of one-year follow-up. When using the Delphi-based international consensus for success after treatment of PJI,^[@bibr54-2046-3758.71.BJR-2017-0323]^ MSIS had a sensitivity of 0 and a specificity of 89%. A second, larger study that evaluated 97 patients undergoing second-stage reimplantation also showed high specificity but low sensitivity for MSIS criteria for diagnosing persistent infection.^[@bibr53-2046-3758.71.BJR-2017-0323]^ While MSIS is clinically useful for ruling out persistent PJI at the time of reimplantation, the lack of its sensitivity precludes its use as a reference test for examining diagnostic tests. It is recommended that studies evaluating infection resolution should focus on long-term follow-up showing infection-free survival and lack of subsequent need for surgical intervention. However, even with such an approach, it is difficult to establish whether a patient develops an infection after reimplantation due to a recurrent infection or due to a new infection, especially when the culture results do not match.

### Obesity and serum biomarkers {#section22-2046-3758.71.BJR-2017-0323}

Obesity is a well-recognized risk for infection following total joint arthroplasty.^[@bibr55-2046-3758.71.BJR-2017-0323]^ In addition to being a risk factor, obesity has also been recognized as an inflammatory state.^[@bibr56-2046-3758.71.BJR-2017-0323]^ This is important to recognize when evaluating inflammatory markers for the diagnosis of PJI, as some obese patients without PJI may have false positive results. Motaghedi et al^[@bibr57-2046-3758.71.BJR-2017-0323]^ prospectively studied 60 patients undergoing THA to measure the inflammatory response by circulating levels of cytokines preoperatively and 24 hours postoperatively. The authors demonstrated enhanced cytokine reactivity and positive correlation between body mass index and IL-1β, IL-6, and TNF-a. Liu et al^[@bibr58-2046-3758.71.BJR-2017-0323]^ evaluated both ESR and CRP in obese and nonobese patients undergoing revision arthroplasty. Using MSIS criteria to identify PJI in their patient population, there was no difference in ESR and CRP values between obese and nonobese patients. However, using ROC curves, a higher cutoff value for diagnosing PJI in obese patients was found (3.6 mg/dl *vs* 1.4 mg/dl).

### Periprosthetic fractures {#section23-2046-3758.71.BJR-2017-0323}

Periprosthetic fractures can occur in patients with PJI. Superimposed PJI in the setting of fractures will certainly change surgical management, but also will be difficult to diagnose due to the acute inflammatory response associated with trauma. Chevillotte et al^[@bibr59-2046-3758.71.BJR-2017-0323]^ retrospectively evaluated 204 patients who sustained periprosthetic fractures after THA in order to characterize the increase in serum inflammatory markers and the positive predictive value for PJI. The authors measured serum levels of ESR, CRP, and WBC; infection was defined as the presence of the same organism on two or more cultures. The prevalence of PJI in periprosthetic fracture was 11.6%. ESR, CRP, and WBC were all poor at identifying infection in this population, with AUC ranging between 0.5 and 0.66. Based on their findings, the authors recommended against using elevated ESR and CRP as reliable predictors of PJI in the setting of periprosthetic fractures and, therefore, additional workup such as hip aspiration in those cases is not indicated based on these marker values alone.

### Metal-on-metal bearing surfaces and corrosion {#section24-2046-3758.71.BJR-2017-0323}

Metal-on-metal (MOM) THA and corrosion at the head-neck junction can lead to an adverse local tissue reaction (ALTR), which can present similarly to PJI and result in purulent-appearing synovial fluid.^[@bibr60-2046-3758.71.BJR-2017-0323],[@bibr61-2046-3758.71.BJR-2017-0323]^ ALTR can be misleading and result in frequent false positive diagnosis of PJI in these patients, making the diagnosis of PJI more challenging. For example, studies have shown that synovial α-defensin, which is generally considered to be an accurate diagnostic test for PJI, is influenced by metallosis, leading to false positive results.^[@bibr62-2046-3758.71.BJR-2017-0323],[@bibr63-2046-3758.71.BJR-2017-0323]^ Unfortunately, serum biomarkers were not found to be any more successful at identifying PJI in MOM THA. Yi et al^[@bibr64-2046-3758.71.BJR-2017-0323]^ found that ESR and CRP had positive predictive values of only 43% and 39%, with AUC of 0.88 and 0.85, respectively. While these markers were found to be somewhat sensitive, positive ESR and CRP in the setting of MOM should be interpreted with caution to avoid a false diagnosis of infection. With regards to corrosion at the metallic modular taper interfaces in THA, one study evaluated ESR and CRP levels in infected and noninfected patients who had dual taper modular stems.^[@bibr65-2046-3758.71.BJR-2017-0323]^ ESR and CRP were both found to have low sensitivity (57% and 29%, respectively) and high specificity (95% and 93%, respectively) for PJI. Again, this data shows limited utility of serum biomarkers in the context of corrosion.

### Other related postoperative complications {#section25-2046-3758.71.BJR-2017-0323}

When CRP is abnormally high after three weeks postoperatively or shows a bimodal pattern (elevation-depression-elevation), infection is suspected. However, a retrospective study examined 76 patients who had a bimodal pattern of CRP change, and found that only 18 patients had surgical site infection, while the remaining 58 patients were diagnosed with respiratory complications (pneumonia or upper respiratory infections), gastrointestinal (ileus or colitis), urinary tract infections, or deep venous thrombosis, or were thought to present with idiopathic elevations.^[@bibr66-2046-3758.71.BJR-2017-0323]^ Therefore, serologic marker thresholds and values should be interpreted in the context of the overall clinical presentation.

Conclusion {#section26-2046-3758.71.BJR-2017-0323}
==========

Serum biomarkers remain a fundamental part of the evaluation and diagnosis of hip and knee PJI. While certain synovial markers have proven to be superior diagnostic tools, serum biomarkers are less invasive screening tests that should be implemented prior to joint aspiration. Currently, ESR and CRP continue their role as first-line screening tests for PJI. However, due to the lack of specificity, these tests are complemented by more specific synovial tests and microbiology findings, and should not be utilized alone in the diagnosis of PJI. Other serum biomarkers have not demonstrated superior sensitivity and have failed to replace ESR and CRP as first-line screening tests. D-dimer appears to be a promising biomarker, but more research is necessary. Our review helped identify factors that can influence serum biomarkers level changes, and the recognition of such factors can help improve their diagnostic utility. As such, we cannot rely on ESR and CRP alone for the diagnosis of PJI prior to second-stage reimplantation, or in metal-on-metal or corrosion cases. The future of serum biomarkers will likely shift towards genomics and proteomics to identify proteins transcribed via messenger RNA in response to infection and sepsis.
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